GAMMA Investing’s Kymera Therapeutics KYMR Stock Holding History

GAMMA Investing’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$91K	Buy	814 +360	+79%	+$41.2K	﹤0.01%	1941
2026 Q2	$52.1K	Buy	454 +98	+28%	+$8.42K	﹤0.01%	2270
2026 Q1	$29.7K	Buy	356 +58	+19%	+$4.59K	﹤0.01%	2505
2025 Q4	$23.2K	Buy	298 +127	+74%	+$8.58K	﹤0.01%	2533
2025 Q3	$9.68K	Sell	171 -15	-8%	-$677	﹤0.01%	2890
2025 Q2	$8.12K	Sell	186 -58	-24%	-$2K	﹤0.01%	2910
2025 Q1	$6.68K	Buy	244 +75	+44%	+$2.73K	﹤0.01%	2946
2024 Q4	$6.8K	Sell	169 -13	-7%	-$587	﹤0.01%	2781
2024 Q3	$8.61K	Buy	182 +60	+49%	+$2.65K	﹤0.01%	2519
2024 Q2	$3.64K	Buy	122 +44	+56%	+$1.52K	﹤0.01%	2679
2024 Q1	$3.14K	Buy	78 +67	+609%	+$2.4K	﹤0.01%	2588
2023 Q4	$361	Buy	+11	New	+$197	﹤0.01%	3023

Other funds holding KYMR

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MAM

Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

GAMMA Investing's KYMR Position: Q3 2026 in Review

GAMMA Investing increased its Kymera Therapeutics (KYMR) stake by 79% in Q3 2026, buying an estimated $41.2K and bringing the position to 814 shares worth $91K. The position accounts for ﹤0.01% of the portfolio, ranked #1941.

GAMMA Investing first reported a position in KYMR in Q4 2023 and has held it in 12 quarters since. 4 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

GAMMA Investing held 814 shares of Kymera Therapeutics worth $91K as of Q3 2026.
GAMMA Investing bought 360 Kymera Therapeutics shares in Q3 2026, an estimated $41.2K.
Kymera Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #1941 holding.
GAMMA Investing first reported a position in Kymera Therapeutics in Q4 2023 and has held it in 12 quarters since.
4 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.